Dashboard
Manage Tickers

IDYAIDEAYA Biosciences, Inc.

Nasdaq ideayabio.com


$ 40.02 $ 0.38 (0.96 %)    

Friday, 12-Jul-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 494.79 $ 2.89 (0.59 %)
DIA $ 400.37 $ 2.69 (0.68 %)
SPY $ 559.91 $ 3.51 (0.63 %)
TLT $ 93.88 $ 0.40 (0.43 %)
GLD $ 223.10 $ -0.14 (-0.06 %)
$ 40
$ 40.28
$ 0.00 x 0
$ 0.00 x 0
$ 39.56 - $ 41.14
$ 20.90 - $ 47.74
2,188,617
na
3B
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-07-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-maintains-overweight-on-ideaya-biosciences-raises-price-target-to-69
JP Morgan Maintains Overweight on IDEAYA B...
07/12/2024 15:06:11

JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and raises the price target from ...

rbc-capital-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-61
RBC Capital Maintains Outperform on IDEAYA...
07/11/2024 14:53:04

RBC Capital analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target f...

why-seastar-medical-holding-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why SeaStar Medical Holding Shares Are Tra...
07/10/2024 17:18:59

kura-sushi-posts-weak-q3-results-joins-legalzoomcom-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Kura Sushi Posts Weak Q3 Results, Joins Le...
07/10/2024 12:01:12

reported-earlier-ideaya-prices-263m-public-offering-of-228572-common-shares-and-pre-funded-warrants-at-35share
Reported Earlier, IDEAYA Prices $263M Publ...
07/10/2024 06:32:51

IDEAYA is selling 7,228,572 shares of common stock and pre-funded warrants to purchase 285,715 shares of common stock in the ...

ideaya-biosciences-intends-to-offer-up-to-200m-of-shares-of-its-common-stock-and-in-lieu-of-common-stock-to-offer-certain-investors-pre-funded-warrants
IDEAYA Biosciences Intends To Offer Up To ...
07/09/2024 20:10:50

btig-maintains-buy-on-ideaya-biosciences-raises-price-target-to-62
BTIG Maintains Buy on IDEAYA Biosciences, ...
07/09/2024 16:36:09

BTIG analyst Justin Zelin maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $55 to $62.

stifel-maintains-buy-on-ideaya-biosciences-maintains-63-price-target
Stifel Maintains Buy on IDEAYA Biosciences...
07/08/2024 17:54:31

Stifel analyst Benjamin Burnett maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and maintains $63 price target.

oppenheimer-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-60
Oppenheimer Maintains Outperform on IDEAYA...
07/08/2024 17:52:01

Oppenheimer analyst Matthew Biegler maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target...

why-arhaus-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Arhaus Shares Are Trading Lower By Aro...
07/08/2024 17:16:55

ideaya-biosciences-highlights-encouraging-preliminary-efficacy-safety-profile-for-patients-with-hard-to-treat-cancer
IDEAYA Biosciences Highlights 'Encouraging...
07/08/2024 16:31:14

IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study...

corning-increases-sales-forecast-joins-morphic-holding-lucid-group-and-other-big-stocks-moving-higher-on-monday
Corning Increases Sales Forecast, Joins Mo...
07/08/2024 14:19:23

mizuho-initiates-coverage-on-ideaya-biosciences-with-outperform-rating-announces-price-target-of-50
Mizuho Initiates Coverage On IDEAYA Biosci...
07/08/2024 11:11:23

Mizuho analyst Graig Suvannavejh initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform rating and announc...

ideaya-biosciences-announced-clinical-data-for-the-ide397-phase-2-monotherapy-expansion-dose-in-methylthioadenosine-phosphorylase-deletion-urothelial-and-non-small-cell-lung-cancer-patients
Ideaya Biosciences Announced Clinical Data...
07/08/2024 10:02:28

~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion ur...

why-paramount-global-shares-are-trading-higher-by-around-8-here-are-20-stocks-moving-premarket
Why Paramount Global Shares Are Trading Hi...
07/08/2024 09:40:41

ideaya-to-present-clinical-data-update-for-ide397-phase-2-monotherapy-expansion-dose-in-mtap-deletion-urothelial-and-lung-cancer-on-july-8-2024-in-investor-webcast
IDEAYA To Present Clinical Data Update For...
07/05/2024 20:13:13

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of tar...

ideaya-biosciences-has-dosed-its-first-patient-in-phase-1-trial-of-ide397-in-combination-with-gileads-trodelvy-sacituzumab-govitecan-hziy-in-patients-with-mtap-deletion-bladder-cancer
Ideaya Biosciences Has Dosed Its First Pat...
06/25/2024 10:02:28

ideaya-biosciences-announced-clinical-program-updates-for-ide397-phase-2-mat2a-inhibitor-targeting-mtap-deletion-solid-tumors
Ideaya Biosciences Announced Clinical Prog...
06/24/2024 10:02:00

Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer p...

stifel-maintains-buy-on-ideaya-biosciences-raises-price-target-to-63
Stifel Maintains Buy on IDEAYA Biosciences...
06/04/2024 12:14:38

Stifel analyst Benjamin Burnett maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $55 t...

ideaya-biosciences-shares-phase-2-results-for-uveal-melanoma-treatment-at-asco-2024
IDEAYA Biosciences Shares Phase 2 Results ...
06/03/2024 10:05:29

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of tar...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)